|
Somatropin (hgh) Anti Aging Treatment up
until the mid 1980's came from the pituitary
glands of cadavers obtained mostly from Africa.
In the mid 1980's cadaver somatropin (hgh) Anti
Aging Treatment was pulled off the market after
it was found to cause a rare disease called Creutzfeld-Jacob
disease in the patients, mostly children, who
were administering it.
In 1985 the Eli Lily pharmaceutical company
managed to synthetically copy the DNA of somatropin
(hgh) Anti
Aging Treatment Hormone exactly in their lab
which the human body naturally produces. Since
then the only somatropin (hgh) Anti
Aging Treatment Hormone
available has been, and still is, recombinant
(biosynthetic). Human growth hormone (HGH), generic
name - Somatotropin, or Somatropin or Somatotrophin
and is only available in an injectable form.
1985, Keith Kelley, M.D., a research scientist
demonstrated that injections of cells that secrete
high amounts of somatropin (hgh) Anti
Aging Treatment Hormone could cause the shriveled
thymus glands in old rats to grow until they
became as large
and healthy as those of young rats. The thymus
gland is the primary organ of the immune system.
Immune system enhancement as a result of an increased
level of somatropin (hgh) Anti
Aging Treatment Hormone
include the following: increased maturation of
neutrophils; higher activity of natural killer
cells; stimulation of macrophages;. increased
production of red blood cells; the manufacture
of new antibodies; increased production of T-cells
and interleukin 2; and the greater proliferation
and activity of lymphocyte cells.
Somatropin (hgh) Anti
Aging Treatment Hormone is
a protein molecule consisting of 191 amino acids.
Genetic engineering, a new technology that emerged
in the 1970's, enables researchers to splice
human genes. The process of gene splicing enabled
researchers to clone the somatropin (hgh) Anti
Aging Treatment Hormone protein after identifying
its exact sequence of DNA. After the growth
hormone
protein was cloned, it was then produced in drug
laboratories in commercial quantities. Consequentially,
biosynthetic somatropin (hgh) Anti
Aging Treatment Hormone
began to be available to medical researchers
for the first time in the 1980's. This genetically
engineered recombinant somatropin (hgh) anti
aging growth hormone is completely identical
to the
somatropin (hgh) human growth hormone naturally
produced by the human pituitary gland and is
therefore referred to as a natural hormone.
Dr. Daniel Rudman, an endocrinologist and medical
researcher from Madison, Wisconsin, conducted
the original and remarkable research on the effect
of somatropin (hgh) anti aging growth hormone
replacement therapy in humans. By the time Dr.
Rudman began
his work in the mid-1980's, the safety of growth
hormone had already been well established through
its use in children with (hgh) human
growth hormone deficiency. Dr. Rudman believed
that the changes in body composition which become
apparent around age 35 had to do with declining
hormone levels. The only method of testing his
hypothesis was to replace somatropin (hgh) Anti
Aging Treatment Hormone in deficient elderly
adults to ascertain if the anti aging
growth
hormone replacement reversed some of the effects
associated with aging. If somatropin (hgh) Anti
Aging Growth Hormone replacement reversed
the changes in body composition (ratios of body
fat and lean
body mass to total body weight) associated with
aging, then somatropin (hgh) anti aging growth
hormone treatment might reverse the loss of bodily
structure and
function that occurs with aging.
To test his theory, Dr. Rudman began a study
by replacing somatropin (hgh) anti aging growth
hormone in
a group of older men to examine its effects on
lean body
mass and body fat in
elderly adults. Dr. Rudman studied 26 men between
the ages of 61 and 80 who had experienced significant
adverse changes in body composition with age,
but who were otherwise healthy. These men were
overweight and had significantly low levels of
somatropin (hgh).
Dr. Rudman selected somatropin (hgh) anti aging
growth hormone as the initial hormone to be replaced
for two reasons. First, he was aware that the
decline in somatropin (hgh) growth hormone
after age 35 was generally accompanied by an
increase in body fat and a decline in lean muscle
mass. Secondly, medical researchers in Sweden
and Denmark had already determined that patients
who were deficient in somatropin (hgh)
growth hormone due to pituitary dysfunction and
had received somatropin (hgh) anti aging growth
hormone replacement treatment became leaner without
altering
their lifestyles, diets or exercise programs,
the men in Rudman's who received somatropin (hgh)
anti aging growth hormone replacement gained
an average of 9% in lean muscle mass while losing
14% of
body fat during their six month test. Bone density
increased and their skin became thicker and firmer.
According to Rudman, the men who received somatropin
(hgh) anti aging growth hormone replacement treatment
during the six months study experienced a reversal
of
the effects of aging by 10 to 20 years. Dr.
Rudman concluded "The overall deterioration
of the body that comes with growing old is not
inevitable."
Rudman's study, published in The New England
Journal of Medicine in 1990, constituted a tremendous
scientific breakthrough in the field of rejuvenation
medicine. The magnitude and the far reaching
impact of Rudman's published study has yet to
be determined. For the first time, medical science,
empowered with the recently developed genetically
engineered recombinant somatropin (hgh) anti
aging growth hormone had discovered a means for
reversing the effects of aging in humans. The
course of
the future and history for mankind was forever
altered.
Dr. Rudman inspired research scientists and
physicians worldwide to investigate and research
the use of somatropin (hgh) anti aging growth
hormone replacement therapy to reverse the effects
of
aging and treat diseases associated with aging.
Concurrent with the time of Dr. Rudman's study,
medical researchers in England, Sweden and Denmark
were also discovering with consistency the remarkable
effects of somatropin (hgh) anti aging growth
hormone replacement treatment. Providing patients
with
(hgh) growth hormone deficiencies
arising from pituitary disease with somatropin
(hgh) anti aging growth hormone treatment had
a remarkable impact upon such patients. These
patients
had been depressed, experiencing low vitality,
fatigue, anxiety, loss of sex drive and were
dying prematurely at twice the average rate due
to cardiovascular disease and other problems
prior to use of somatropin (hgh) anti aging growth
hormone. Somatropin (hgh) anti aging growth hormone
replacement treatment brought the patients out
of their depression and fatigue into higher quality,
productive and happy lives.
In 1996, the New England Journal of Medicine,
reported somatropin (hgh) anti aging hormone
replacement treatment had reversed heart failure.
Today the National Institute On Aging is conducting
six clinical trials in a multimillion dollar
study of somatropin (hgh) anti aging growth hormone
replacement treatment to further confirm that
somatropin growth hormone retards
and reverses
aging.
In August 1996, the Food and Drug Administration
approved the use of somatropin (hgh) anti aging
growth hormone in adults with growth hormone
deficiency
due to pituitary or hypothalamic disease, injury,
surgery or radiation therapy. Since the studies
conducted in England, Sweden and Denmark since
1985 clearly demonstrate that aging is a pituitary
disease, the recent FDA approval of adult somatropin
(hgh) anti aging growth hormone replacement treatment
may now allow physicians in the United States
to prescribe somatropin (hgh) anti aging growth
hormone for adults with low levels of IGF-1,
without
knowing why there is a failure of the pituitary
gland to produce adequate amounts of
(hgh) human growth hormone. This is a legal rather
than a medical question.
The FDA approved adult human growth hormone
(hgh) replacement treatment for adults with human
growth hormone hgh deficiency syndrome after
reviewing clinical data submitted to it
by the Eli Lilly Company. Lilly secured FDA approval
for adult human growth hormone (hgh)
replacement therapy because data secured from
Lilly's clinical trials demonstrated that somatropin
anti aging growth hormone (hgh) replacement treatment
resulted in an increase of lean muscle mass,
a decrease in body fat, an increase in exercise
capacity and an increase in quality of life among
adults with human growth hormone (hgh)
deficiency. More
info on Somatropin HGH -Anti Aging Treatment.>>>
Somatropin - HGH - Anti Aging Treatment
|
